Overview
Glial fibrillary acidic protein is an intermediate filament type III protein that is uniquely expressed in astrocytes of the central nervous system, non-myelinating Schwann cells of the peripheral nervous system, and enteric glial cells. It plays a key role in maintaining the cytoskeletal structure and mechanical strength of glial cells. GFAP supports neighboring neurons and contributes to the integrity of the blood–brain barrier.
Its gene expression is regulated by nuclear receptor hormones, growth factors, and inflammatory mediators. Because of its restricted expression pattern, GFAP is widely used as a central nervous system marker and serves as an important indicator of astrocytic activation and injury.
Symptoms
Clinical manifestations associated with altered GFAP levels are related to underlying neurological damage rather than direct effects of the protein itself. Elevated GFAP levels are observed in conditions involving astrocytic injury, such as traumatic brain injury, stroke, intracranial hemorrhage, and neurodegenerative disorders.
Patients may present with neurological symptoms including headache, altered consciousness, cognitive decline, memory impairment, focal neurological deficits, and motor or sensory disturbances. In chronic neurodegenerative diseases, symptoms may progress gradually and include dementia, movement disorders, and behavioral changes. In acute brain injury, symptoms often correlate with the severity of tissue damage and astrocyte disruption.
Causes
Increased GFAP levels are caused by damage or activation of astrocytes in the central nervous system. Traumatic brain injury leads to astrocytic disruption and release of GFAP and its breakdown products into blood and cerebrospinal fluid. Ischemic brain injury and stroke result in astrocyte damage due to hypoxia and inflammation.
Neurodegenerative diseases such as Alzheimer’s disease, Parkinsonism, and multiple sclerosis are associated with chronic astrocytic activation and elevated GFAP expression. Brain tumors, particularly gliomas and astrocytomas, show increased GFAP due to their glial origin. Intracranial hemorrhage and other structural brain lesions also contribute to raised GFAP levels. In gastrointestinal pathology, GFAP expression is noted in neuroendocrine tumors of the stomach due to the involvement of enteric glial cells.
Risk Factors
Risk factors for abnormal GFAP levels include traumatic head injury, cerebrovascular disease, and conditions causing hypoxic or ischemic brain damage. Advancing age increases susceptibility to neurodegenerative disorders associated with astrocytic activation. Individuals with a history of stroke, dementia, or chronic inflammatory neurological diseases are at higher risk.
The presence of brain tumors, especially those of glial origin, significantly raises GFAP expression. Patients with repeated head trauma or intracranial bleeding are also at increased risk. Chronic neurological conditions may lead to fluctuating GFAP levels, complicating long-term interpretation.
Prevention
Prevention of GFAP elevation focuses on reducing the risk and severity of central nervous system injury. Preventive strategies include minimizing traumatic brain injury through safety measures and early medical intervention. Prompt management of stroke and ischemic events helps limit astrocytic damage. Early diagnosis and treatment of neurodegenerative diseases may reduce the progression of astrocytic injury.
Proper clinical assessment combined with laboratory testing supports the timely detection of neurological damage. Standardized sample collection, handling, and storage are essential for accurate GFAP measurement. Integrating GFAP testing with clinical evaluation and imaging improves early recognition of central nervous system pathology and supports appropriate patient management.
